Phacilitate 2020: FDA commercial cell and gene therapy forecast ‘unlikely’
Manufacturing issues and a scarcity of new commercial products leave predictions that 10-20 cell and gene therapy approvals each year by 2025 somewhat fanciful, says Dark Horse Consulting. In his plenary address at the Phacilitate conference yesterday, Anthony Davies, founder of cell and gene the ...
Eli Lilly says its injectables pipeline and Trump-era tax laws prompted the decision to build new plant in North Carolina.
Earlier this week L ...
The newly formed Center for Breakthrough Medicines is building what it claims to be the world’s largest third-party cell and gene production fa ...
Thermo Fisher claims to be the “leading outsource provider of viral vector manufacturing,” nine months after entering the space through the a ...
GE Healthcare Life Sciences says a single-use kit plant it is building in Grens, Switzerland will serve cell and gene therapy firms in the EU and ...
Recent Tweets
-
RT @Dan5tanton: And here is the full story from @phacilitate courtesy of @BioProInsider 'CDMO aims ‘big’ in $1.2bn push to deliver… https://t.co/bDTRAi1MIm
22 hours ago
-
RT @Dan5tanton: FDA cell and gene therapy forecast ‘unlikely’ - the opinion from Phacilitate #PLW2020 as number of commercialized t… https://t.co/nLyOAHZgtt
2 days ago
-
RT @Dan5tanton: Mixture of pride of advancement but disappointment in relatively few commercial cell and gene products is the feeli… https://t.co/UWblLuPcuq
2 days ago
-
RT @Dan5tanton: $IOVA iovance admits TIL therapies with 22 day manufacturing process and potential gene editing added will be very… https://t.co/iwW2X1s5m4
3 days ago
